Seminars in Cutaneous Medicine and Surgery 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Biomarkers for immune therapy in melanoma.
Authors: Johnson DB, Chon J, Johnson MR, Balko JM
Abstract
Immune checkpoint inhibitors have dramatically transformed melanoma treatment options. However, intrinsic and acquired resistance remain fundamental limitations to extending the benefits to all patients. Understanding molecular and clinical features that correlate with response to treatment (biomarkers) may unravel therapeutic resistance, assist in treatment decision-making, and facilitate drug development. An intensive effort to characterize these biomarkers is underway. Herein, we highlight promising molecular biomarkers involving the tumor micro...
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Immunotherapy for melanoma.
Authors: Cuevas LM, Daud AI
Abstract
Immunotherapy for the treatment of advanced melanoma has become a primary treatment in the clinic. Current therapies include systemic cytokines, immune checkpoint inhibitors, and localized intratumoral therapies. Checkpoint inhibitors block natural pathways that dampen or inhibit an immune response to stimulus. These pathways include programmed cell death 1 receptor/programmed death-ligand 1 and cytotoxic T lymphocyte antigen-4. Systemic immunotherapies have proven to be effective in clinical trials both as monotherapy and in combination therapy. Oncolytic viruses are u...
Source: Seminars in Cutaneous Medicine and Surgery - July 25, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar.
Authors: Baldwin HE, Stein Gold LF, Gordon KB, Green JB, Leonardi CL, Sengelmann RD
Abstract
Updates on managing some of the most common dermatologic conditions for which patients seek care illuminated presentations at the Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar®. This educational supplement summarizes the highlights of clinical sessions presented during this CME/CE conference. Treatment of psoriasis has continued to advance, with three interleukin (IL)-17 antagonists approved by the US Food and Drug Administration (FDA) and a fourth in phase 3 trials. An authority on th...
Source: Seminars in Cutaneous Medicine and Surgery - July 18, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Small Molecules for Psoriasis.
Authors: Leonardi CL
Abstract
Acitretin is an older, oral, non-immunosuppressive medication for the treatment of psoriasis. Tofacitinib is an oral Janus kinase inhibitor that has been studied for use in psoriasis. Each offers efficacy in certain settings and patient types but carries substantial safety risks. Semin Cutan Med Surg 35(supp4):S65-S66.
PMID: 29850659 [PubMed] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - June 3, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
New Therapies for Psoriasis.
Authors: Strober BE
Abstract
Among the newer medications for treating psoriasis are the interleukin-17A inhibitor secukinumab and the phosphodiesterase 4 inhibitor apremilast. Secukinumab offers a level of efficacy greater than that of the tumor necrosis factor-α inhibitor adalimumab. Apremilast is associated with lower levels of efficacy than the biologic therapies for psoriasis. Apremilast may cause diarrhea and nausea and is associated with weight loss and rare instances of depression. Semin Cutan Med Surg 35(supp4):S71-S73.
PMID: 29850660 [PubMed] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - June 3, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
This article reviews the data documenting the efficacy and safety of three types of biologics. Semin Cutan Med Surg 35(supp4):S74-S77.
PMID: 29850661 [PubMed] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - June 3, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Cutaneous Lymphoma, Introduction.
Authors: Pincus LB
PMID: 29719013 [PubMed - in process] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - May 5, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar ™ Scientific Abstracts.
Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar™ Scientific Abstracts.
Semin Cutan Med Surg. 2018 Jun;37(2):S1-S38
Authors:
PMID: 29719009 [PubMed - in process] (Source: Seminars in Cutaneous Medicine and Surgery)
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Authors: Cerroni L
Abstract
Mycosis fungoides (MF) is the most common type of cutaneous lymphoma. The term MF should be used only for the classical presentation of the disease characterized by the evolution of patches, plaques, and tumors or for variants showing a similar clinical course. MF is divided into 3 clinical phases: patch, plaque, and tumor stage, and the clinical course is usually protracted over years or decades. Histopathologically, MF is characterized by an epidermotropic infiltrate of T lymphocytes that displays in most cases a helper phenotype. Cytotoxic variants are well described and do n...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment.
Authors: Willemze R
Abstract
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, which typically presents with erythematous patches and plaques, histopathologically characterized by superficial infiltrates of small to mediumsized atypical epidermotropic T cells. Apart from this classic type of MF, many clinical and/or histopathologic variants have been described. Correct diagnosis of these MF variants is important, but may be difficult, because they may mimic a wide variety of inflammatory skin diseases. In this review, clinical and histopathologic characteristics of distinct varia...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
S ézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.
Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.
Semin Cutan Med Surg. 2018 Mar;37(1):18-23
Authors: Spicknall KE
Abstract
Sézary syndrome (SS) is a rare subtype of cutaneous T-cell lymphoma marked by erythroderma, circulating neoplastic T cells, and poor prognosis. Its low incidence has made the study of its etiology, immunologic/molecular pathways, and effective treatments difficult. Because histopathology may be nonspecific in SS, microscopic findings must be correlated with the clinical presentation and the results of blood evalua...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Authors: Kempf W, Kerl K, Mitteldorf C
Abstract
Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPD) are the second most common form of cutaneous T-cell lymphoma. CD30+ LPD include lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, and borderline lesions. Despite expression of CD30 by the neoplastic cells as the hallmark of these disorders, they differ in their clinical presentation and histological features as well as the course, the prognosis, and consecutively in the treatment. Diagnosis of CD30+ LPD and distinction from the broad spectrum of differential diagnoses ess...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
NK/T-cell lymphoma, nasal type, γδ T-cell lymphoma, and CD8-positive epidermotropic T-cell lymphoma-clinical and histopathologic features, differential diagnosis, and treatment.
Authors: Geller S, Myskowski PL, Pulitzer M
Abstract
The cytotoxic lymphomas of the skin constitute a heterogeneous group of rare lymphoproliferative diseases that are derived from mature T cells and natural killer (NK) cells that express cytotoxic molecules (T-cell intracellular antigen- 1, granzyme A/B, and perforin). Although frequently characterized by an aggressive course and poor prognosis, these diseases can have variable clinical behavior. This review delivers up-to-date information about the clinical presentation, histopathologic features, differential diagnosis, and therapy of extranodal NK/T-cel...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment.
Authors: Gru AA, Wick MR, Eid M
Abstract
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder usually presents as a slow-growing and asymptomatic solitary lesion in the form of a nodule or tumor in the head and neck region. By definition, it is histologically characterized by small- to medium-sized CD4+ lymphocytes involving the dermis in a dense and either nodular or diffuse pattern. Epidermotropism should be absent or minimal. Tumor cells are accompanied by numerous reactive B cells, plasma cells, histiocytes, and eosinophils. This lymphoproliferative disorder is characterized by the e...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Primary cutaneous B-cell lymphomas- clinical and histopathologic features, differential diagnosis, and treatment.
Authors: Chen ST, Barnes J, Duncan L
Abstract
Cutaneous B-cell lymphomas (CBCLs) are a heterogeneous group of diseases that can have variable presentations, prognoses, and treatments. The proper identification of a CBCL hinges on proper histopathologic and clinical evaluation. Comprising 25% to 30% of the primary cutaneous lymphomas, incident cases of CBCL are rare. Given the variable natural history of the CBCL, proper classification is critical so that patients are treated appropriately. CBCLs can be divided into 2 main groups: indolent and aggressive. Indolent CBCLs include primary cutaneous follicle ce...
Source: Seminars in Cutaneous Medicine and Surgery - May 4, 2018 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
